dc.contributor.author | Durcan E. | |
dc.contributor.author | Keskin F.E. | |
dc.contributor.author | Ozkaya H.M. | |
dc.contributor.author | Sirolu S. | |
dc.contributor.author | Sahin S. | |
dc.contributor.author | Korkmaz O.P. | |
dc.contributor.author | Gazioglu N. | |
dc.date.accessioned | 2024-02-04T13:30:08Z | |
dc.date.available | 2024-02-04T13:30:08Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 09477349 | |
dc.identifier.uri | https://doi.org/10.1055/a-1523-7216 | |
dc.identifier.uri | http://hdl.handle.net/11446/4850 | |
dc.description.abstract | Purpose To investigate the relationship of Fibroblast Growth Factor Receptor-4 (FGFR-4) expression with radiologic, pathologic, and clinical parameters in pituitary adenomas. Methods Among 307 patients who underwent pituitary surgery for a pituitary adenoma between 2000 and 2015, we included 161 patients (53 gonadotroph, 26 corticotroph, 25 null cell, 22 lactotroph, 13 somatotroph, 8 adenomas with unusual combination, 7 Pit-1 positive adenomas, and 7 lactosomatotroph) based on availability of pathology specimens. Patients' radiologic, pathologic, and clinical parameters were determined. FGFR-4 immunostaining was evaluated using a semi-quantitative histologic score (H-score). Results The mean follow-up period was 61 (IQR=32-84) months. The median H-scores for FGFR-4 were higher in patients without remission, those with residual lesion, and T2-hyperintense adenoma (p<0.05). Ki-67 level was higher in patients without remission compared to those in remission (p<0.05). The mean Ki-67 levels did not differ between patients with and without residual lesion or T2-hyperintense tumor (p>0.05). There was no significant difference (p>0.05) when the H-score and Ki-67 levels were assessed in terms of sex, sellar-dural invasion, Knosp and a grading system for superior, inferior, parasellar, anterior and posterior tumor extension Classification, tumor function or presence of poor subtype. Adenomas with Ki-67 expression ?3% had higher FGFR4 expression levels than those with <3% expression (p=0.002). There was a weak positive correlation between H-score and Ki-67 (p=0.011; r=0.201). Conclusions Higher levels of FGFR-4 in pituitary adenomas could be use a marker for more aggressive tumor behavior. © 2021. Thieme. All rights reserved. | en_US |
dc.description.sponsorship | 46492 | en_US |
dc.description.sponsorship | The study was supported by the Research Fund of Istanbul University, Istanbul, Turkey (Project No: 46492). | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Georg Thieme Verlag | en_US |
dc.relation.ispartof | Experimental and Clinical Endocrinology and Diabetes | en_US |
dc.identifier.doi | 10.1055/a-1523-7216 | |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | FGFR-4 | en_US |
dc.subject | Ki-67 | en_US |
dc.subject | pituitary adenomas | en_US |
dc.subject | tumor aggressiveness | en_US |
dc.subject | fibroblast growth factor receptor 4 | en_US |
dc.subject | Ki 67 antigen | en_US |
dc.subject | transcription factor Pit 1 | en_US |
dc.subject | FGFR4 protein, human | en_US |
dc.subject | fibroblast growth factor receptor 4 | en_US |
dc.subject | Ki 67 antigen | en_US |
dc.subject | MKI67 protein, human | en_US |
dc.subject | tumor marker | en_US |
dc.subject | ACTH secreting adenoma | en_US |
dc.subject | adult | en_US |
dc.subject | Article | en_US |
dc.subject | cavernous sinus | en_US |
dc.subject | female | en_US |
dc.subject | follow up | en_US |
dc.subject | gonadotroph adenoma | en_US |
dc.subject | growth hormone secreting adenoma | en_US |
dc.subject | histopathology | en_US |
dc.subject | human | en_US |
dc.subject | human tissue | en_US |
dc.subject | hypophysis adenoma | en_US |
dc.subject | hypophysis tissue | en_US |
dc.subject | immunohistochemistry | en_US |
dc.subject | labeling index | en_US |
dc.subject | macroadenoma | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | middle aged | en_US |
dc.subject | minimal residual disease | en_US |
dc.subject | mitosis index | en_US |
dc.subject | mitosis rate | en_US |
dc.subject | nuclear magnetic resonance imaging | en_US |
dc.subject | null cell adenoma | en_US |
dc.subject | pituitary surgery | en_US |
dc.subject | predictive value | en_US |
dc.subject | prolactinoma | en_US |
dc.subject | protein expression | en_US |
dc.subject | receiver operating characteristic | en_US |
dc.subject | sella turcica | en_US |
dc.subject | sensitivity and specificity | en_US |
dc.subject | tumor classification | en_US |
dc.subject | tumor diagnosis | en_US |
dc.subject | tumor invasion | en_US |
dc.subject | tumor regression | en_US |
dc.subject | tumor volume | en_US |
dc.subject | adenoma | en_US |
dc.subject | hypophysis tumor | en_US |
dc.subject | metabolism | en_US |
dc.subject | pathology | en_US |
dc.subject | Adenoma | en_US |
dc.subject | Adult | en_US |
dc.subject | Biomarkers, Tumor | en_US |
dc.subject | Female | en_US |
dc.subject | Follow-Up Studies | en_US |
dc.subject | Humans | en_US |
dc.subject | Ki-67 Antigen | en_US |
dc.subject | Male | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Pituitary Neoplasms | en_US |
dc.subject | Receptor, Fibroblast Growth Factor, Type 4 | en_US |
dc.title | Fibroblast Growth Factor Receptor-4 Expression in Pituitary Adenomas is Associated with Aggressive Tumor Features | en_US |
dc.type | article | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.volume | 130 | en_US |
dc.identifier.startpage | 125 | en_US |
dc.identifier.endpage | 133 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | Durcan, E., Division of Endocrinology-Metabolism and Diabetes, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Kocamustafapasa Street No:53, Fatih, Istanbul, 34098, Turkey; Keskin, F.E., Division of Endocrinology and Metabolism, Department of Internal Medicine, T.C. Demiroglu Bilim University, Istanbul, Turkey; Ozkaya, H.M., Division of Endocrinology-Metabolism and Diabetes, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Kocamustafapasa Street No:53, Fatih, Istanbul, 34098, Turkey; Sirolu, S., Department of Radiodiagnostic, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey; Sahin, S., Division of Endocrinology-Metabolism and Diabetes, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Kocamustafapasa Street No:53, Fatih, Istanbul, 34098, Turkey; Korkmaz, O.P., Division of Endocrinology-Metabolism and Diabetes, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Kocamustafapasa Street No:53, Fatih, Istanbul, 34098, Turkey; Gazioglu, N., Department of Neurosurgery, T.C. Demiroglu Bilim University, Istanbul, Turkey; Tanriover, N., Department of Neurosurgery, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey; Comun | en_US |
dc.identifier.pmid | 34255320 | en_US |
dc.identifier.scopus | 2-s2.0-85110576496 | en_US |
dc.authorscopusid | 57189307128 | |
dc.authorscopusid | 56118245000 | |
dc.authorscopusid | 37009373600 | |
dc.authorscopusid | 57193006379 | |
dc.authorscopusid | 57208882907 | |
dc.authorscopusid | 57210185147 | |
dc.authorscopusid | 6601973313 | |